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Abstract
Introduction: In nonpregnant “quitters,” adherence to nicotine replacement therapy (NRT) increases 
smoking cessation. We investigated relationships between adherence to placebo or NRT patches 
and cessation in pregnancy, including an assessment of reverse causation and whether any adher-
ence: cessation relationship is moderated when using nicotine or placebo patches.
Methods: Using data from 1050 pregnant trial participants, regression models investigated asso-
ciations between maternal characteristics, adherence and smoking cessation.
Results: Adherence during the first month was associated with lower baseline cotinine concentra-
tions (β −0.08, 95% confidence interval [CI] −0.15 to −0.01) and randomization to NRT (β 2.59, 95% 
CI 1.50 to 3.68). Adherence during both treatment months was associated with being randomized 
to NRT (β 0.51, 95% CI 0.29 to 0.72) and inversely associated with higher nicotine dependence. 
Adherence with either NRT or placebo was associated with cessation at 1 month (odds ratio [OR] 
1.11, 95% CI 1.08 to 1.13) and delivery (OR 1.06, 95% CI 1.03 to 1.09), but no such association was 
observed in the subgroup where reverse causation was not possible. Amongst all women, greater 
adherence to nicotine patches was associated with increased cessation (OR 2.47, 95% CI 1.32 to 
4.63) but greater adherence to placebo was not (OR 0.98, 95% CI: 0.44 to 2.18).
Conclusion: Women who were more adherent to NRT were more likely to achieve abstinence; more 
nicotine dependent women probably showed lower adherence to NRT because they relapsed to smok-
ing more quickly. The interaction between nicotine-containing patches and adherence for cessation sug-
gests that the association between adherence with nicotine patches and cessation may be partly causal.
Implications: This study used placebo randomized controlled trial data to investigate both associa-
tions between women’s characteristics and adherence to NRT patch treatment, and the relationship 
between adherence to NRT patch treatment and odds of cessation in pregnant quitters. Greater 
adherence was seen with NRT patches, and greater adherence with NRT patches increased the odds 
of smoking cessation. A likely explanation for findings is that NRT patches, if used sufficiently, may 
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be effective for at least some pregnant women who try to stop smoking. Trials testing interventions 
which encourage women’s adherence to higher dose NRT are indicated.
Introduction
Smoking in pregnancy is a substantial cause of ill health and the 
leading preventable cause of poor health outcomes for both moth-
ers and babies.1 Nicotine replacement therapy (NRT) is an effective 
medication for smoking cessation2 but it is unclear whether it works 
in pregnancy.3 A potential reason for the apparently lower efficacy of 
NRT in pregnancy is poor adherence to treatment; from randomized 
controlled trials included in a Cochrane review, only 7%–30% of 
pregnant women who received NRT reported finishing a complete 
course.3 Adherence to NRT in nonpregnant smokers appears to be 
much higher.4–7 The reasons for low adherence to NRT amongst 
pregnant smokers are not well researched but qualitative work sug-
gests women’s attitudes are at least partially responsible as some 
pregnant smokers have substantial concerns about potential fetal 
harms from nicotine.8 However, as nicotine metabolism accelerates 
in pregnancy,9,10 pregnant smokers may need higher nicotine doses to 
combat nicotine withdrawal, and high levels of treatment adherence 
may be particularly important for these women to achieve cessation.
In nonpregnant smokers, adherence to NRT is causally associated 
with smoking cessation4–7; prescribing more NRT patches is associ-
ated with greater use of NRT which in turn is positively associated 
with achieving cessation.5 Additionally “reverse causation” or stop-
ping NRT treatment because of relapse to smoking does not appear 
to explain the adherence-cessation association.4–7 The significance of 
strong adherence to NRT by pregnant “quitters” is less well defined 
and to date has only been investigated in one study.11 This study found 
that NRT used within 48 hours of quitting was associated with longer 
term use and also that women who used NRT for longer periods were 
more likely to be abstinent at 38 weeks gestation.11 However, these 
analyses did not account for confounding factors, so should be inter-
preted with caution. We hypothesize that efficacy of NRT in preg-
nancy is dependent on high levels of treatment adherence and, in this 
paper, we use data from a large trial of NRT used in pregnancy (the 
SNAP trial)12 to further investigate the relationship between adher-
ence to NRT and smoking cessation amongst pregnant smokers. If our 
hypothesis is correct, one would expect to find a positive association 
between greater adherence to NRT and cessation that is not due to 
reverse causation (ie, that is not due to smokers that have lapsed to 
smoking not achieving cessation, as has been found in nonpregnant 
smokers).7 In a series of analyses, therefore, we (1) investigate which 
characteristics of participants are associated with adherence to trial 
treatments; (2) determine the nature of any relationship between trial 
participants’ adherence to treatment patches and the odds of smok-
ing cessation, including the extent to which this might be explained 
by their characteristics; (3) investigate whether reverse causation 
explains the apparent adherence-cessation association; and (4) deter-
mine whether there is evidence of an interaction between adherence, 
type of patch used (ie, placebo or nicotine) and the odds of cessation.
Methods
Data Source, Baseline Variables and Provision of Trial 
Patches
Data collected during the SNAP trial12 were used to investigate adher-
ence to standard dose 15mg/16h NRT or placebo transdermal patches 
when used for smoking cessation in pregnancy. Prior to randomization, 
data were collected on: age, ethnicity, age full-time education com-
pleted, number of cigarettes smoked before pregnancy and currently, 
time after waking until first cigarette of the day, partners’ smoking sta-
tus, parity, gestational age, body mass index (BMI) and previous use of 
NRT in the current pregnancy. Saliva samples for cotinine estimation 
were also taken. Before randomization, participants were informed to 
stop using patches if they restarted smoking, because of the potential 
importance with regards to fetal health. After randomization, patches 
were issued in 4-week batches; women were asked to begin using them 
on their quit dates and, if they were abstinent at 1 month and wished 
to receive more, they then were given a second batch.
Adherence and Cessation Definitions
Adherence
At 1 month and delivery, participants were asked about their smoking 
behavior and the number of days on which they had used trial patches. 
At 1 month participants could report using patches for a maximum 
of 28 days and, at delivery for a maximum of 56 days; adherence was 
measured with respect to these values. Women for whom there were 
no adherence data were considered to have zero days’ adherence.
Cessation
At 1 month, participants were asked about their smoking status in 
the last 24 hours and also since their quit date, which had been set 
shortly after randomization. If they reported abstinence from their 
quit date to 1 month postquit, this was validated using an exhaled 
carbon monoxide reading (<8 ppm). At delivery, participants who 
reported abstinence between their quit date and delivery had this 
validated using exhaled carbon monoxide measurement (<8 ppm) 
and/or saliva cotinine estimation (<10 ng/ml). Those who reported 
prolonged abstinence (ie, smoking no more than five cigarettes) from 
quit date to respective follow-up points and in whom this was vali-
dated, were considered to have achieved validated cessation.
Transformation of Adherence Data
Adherence data reported at 1 month was deemed to be sufficiently 
normally distributed that transformation was not needed; however, 
adherence data reported at delivery was square root transformed to 
adjust for the positive skew of the data (Skewness 1.80, Kurtosis: 6.62, 
where normal distributions have skewness and kurtosis of 0 and 3, 
respectively). The number of days that trial patches were used is a 
count measure and transformation of this meant that adherence, when 
used as an outcome, better fitted the assumptions of linear regression 
by assuming a more normal distribution.13 The transformed variable 
was only used when adherence was an outcome variable, that is, in 
analyses investigating the relationship between maternal characteris-
tics and adherence. The results of the regression findings were then 
back-transformed to allow clinically meaningful interpretations.
Analysis Strategies
Investigation of Relationship Between Women’s Characteristics and 
Adherence to Trial Patches (Objective I)
Linear regression analyses were used to assess univariable asso-
ciations between data describing participants’ characteristics at 
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baseline and adherence reported at 1 month postquit date and also 
at delivery. All baseline variables were tested for collinearity; how-
ever, no associations were found. Then, the following model building 
strategy was performed to construct two multivariable parsimonious 
models using adherence data from 1 month and delivery as outcome 
variables. Firstly, all variables found in univariable analyses to be 
significant at a level of P ≤ .05 were entered into a multivariable 
model and those subsequently found to be nonsignificant within this 
(P > .05) were then removed. Next, variables which had not been 
found to have significant univariable associations with adherence 
were added one at a time to the multivariable models to determine if 
they were now associated with adherence to treatment.
Investigation of the Relationship Between Adherence and 
Cessation and Whether Confounding Explains This (Objective II)
Multivariable logistic regression analyses were constructed for vali-
dated cessation at 1 month and delivery, using the same model build-
ing strategy as described above. Treatment assignment was included 
as an a priori confounder of this association, with the rationale being 
that an effect of adherence to treatment would only be expected in 
the group receiving nicotine patches. In addition, heaviness of smok-
ing index (HSI) was also considered an a priori confounder as it is 
known to be a marker of addiction to tobacco.
Investigation of Reverse Causation as an Explanation for 
Adherence-Cessation Association (Objective III)
To investigate whether reverse causation may explain an appar-
ent association between adherence and cessation, we conducted an 
analysis restricted to women who were assigned NRT patches and 
recorded as abstinent from smoking at 1  month following their 
quit date. In this group, any observed association between adher-
ence and cessation could not be explained by reverse causation, 
as all women were still abstinent and restarting smoking would 
not explain their decision to stop using assigned NRT patches. 
This analysis used early adherence, whilst abstinent, as a proxy for 
later adherence and operated under the assumption that women 
with high early adherence would also have greater adherence after 
1  month into the trial when their abstinence from smoking was 
measured for the first time and this later adherence would be caus-
ally associated with abstinence. Thus, a logistic regression analysis 
was used to compare the odds of cessation at delivery and adher-
ence to NRT patches, ascertained using the median split in the 
number of days NRT patches were used within the first 28 days 
following their quit date.
Investigation of Whether or not a Treatment  
Assignment-Adherence Interaction Exists for Smoking  
Cessation (Objective IV)
Logistic regression analyses were performed to assess whether the 
interaction between NRT assignment and adherence to patches 
(using median split as defined above) was significantly associated 
with the odds of cessation at delivery. If high adherence to NRT 
patches was significantly associated with higher rates of abstinence 
than high adherence to placebo patches, this would demonstrate that 
NRT patches have a greater effect on cessation the more they are 
used. We performed a sensitivity analysis to assess the significance of 
the interaction test between adherence and treatment assignment on 
the odds of cessation as delivery in a subgroup of women who were 
validated as abstinent at 1 month, where reverse causation would 
not be possible.
Complete case analyses were conducted for all objectives. All 
analyses were conducted using Stata 13.1 (College Station, TX).
Results
Of 1050 women randomized in the SNAP trial,12 analyses for objec-
tives I, II and the first analysis to address objective IV, were conducted 
in 957 (91.1%) women who had no missing data for baseline char-
acteristics. Analyses to address objective III and the second analysis 
addressing objective IV were conducted within the 167 (15.9%) 
women who were abstinent up until 1 month postquit date. Women 
who did not report the age they left full-time education all failed to 
achieve cessation, and so were excluded from the analysis (n = 14, 
1.3%). We also excluded 80 women (7.6% nondisclosure rate) where 
there were no data on cotinine concentration at baseline. Adherence 
data were available for 865 women at 1 month and for 981 women 
at delivery. Missing data for adherence was imputed as zero days used 
for the women included in the analysis as it was likely that women 
who did not report adherence had lapsed to smoking and were not 
using patches; this imputation was made for 15.9% and 6.4% of par-
ticipants at 1 month and delivery respectively. The baseline maternal 
characteristics of the main study group (N = 957) and the restricted 
study group (N = 167) are included in Table 1 and Table 2, respectively.
Adherence
Maternal age, level of education, ethnicity, primiparity and gestational 
age amongst low and high adherers were similar for women included 
in the complete case analyses (n = 957) for objectives I and II (Table 1). 
The baseline characteristics of the 167 women in the restricted group, 
which was used in the analyses for objectives III and IV, were simi-
lar to the 957 women analyzed in objectives I and II with respect to 
maternal age and gestation (Table  2). The following are adherence 
statistics for the 167 women who were abstinent for at least 1 month 
and who comprised the analysis sample for objectives III and IV. 
One hundred twenty-six (75.4%) women were classified as “highly 
adherent” (ie, used ≥7 days’ patches) and had used patches for a mean 
of 20.5 (SD 5.7) days. Forty-one (24.6%) women had lower adher-
ence (≤6 days) and used patches for a mean of 3.6 (SD 2.0) days. At 
delivery, 126 (75.4%) women were classified as highly adherent and 
reported using patches on average for 31.5 (SD 16.4) days and 41 
(24.6%) were less adherent women who reported using patches for an 
average of 3.6 (SD 2.0) days. A likelihood ratio test was used to test 
whether adherence decreased in a nonlinear fashion. These tests sug-
gested that adherence decreased in a linear fashion at 1 month follow-
up (P =  .121) and at delivery (P =  .999). Therefore, adherence was 
included as a continuous variable in the subsequent analyses.
Investigation of Relationship Between Women’s 
Characteristics and Adherence to Trial Patches 
(Objective I)
Factors associated with adherence at 1  month and delivery are 
detailed in Table 3 and Table 4. At 1 month, univariable analyses 
showed that women with higher HSI scores and higher baseline coti-
nine level had lower odds of adherence, whilst women assigned to 
NRT and who had remained in full-time education beyond the age 
of 16 years had higher odds of adherence. In a multivariable analy-
sis, only the inverse association with baseline cotinine (adjusted β 
−0.08, 95% confidence interval [CI] −0.15 to −0.01, P = .020) and 
treatment assignment to NRT (adjusted β 2.59, 95% CI 1.50 to 
3.68, P < .001) remained significant (Table 3).
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At delivery, univariable analyses showed that treatment assign-
ment to NRT and age when full-time education was completed were 
associated with increased odds of adherence. A higher HSI score was 
also found to be inversely associated with the odds of adherence. 
A  multivariable analysis of these factors found that HSI’s inverse 
association (adjusted β −0.27, 95% CI −0.50 to −0.05, P < .001) 
and treatment assignment to NRT (adjusted β 0.51, 95% CI 0.29 to 
0.72, P < .001) remained significant (Table 4).
Investigation of Relationship Between Adherence 
and Cessation and Whether Potential Confounding 
Explains This (Objective II)
After adjustment for baseline characteristics, at 1 month, for each 
extra day’s use of trial patches (ie, placebo or nicotine-containing), 
the odds of cessation at 1 month increased by 11% (adjusted odds 
ratio [OR] 1.11, 95% CI 1.08 to 1.13, P < .001; Table  5). After 
adjustment for baseline characteristics, at delivery, the odds of cessa-
tion increased by 6% (adjusted OR 1.06, 95% CI 1.03 to 1.09, P < 
.001) for each extra day trial patches were used (Table 6).
Investigation of Reverse Causation as an Explanation 
for Adherence-Cessation Association (Objective III)
Within the 167 women who were abstinent from quit date until 
1 month, there was no statistically significant difference in the odds 
of cessation at delivery between women who were highly adherent 
and those who had “lower adherence” (OR: 0.63, 95% CI: 0.31 to 
1.27, P = .196).
Investigation of Whether a Treatment Assignment-
Adherence Interaction Exists for Smoking Cessation 
(Objective IV)
In the full sample of pregnant smokers (n = 957), the likelihood ratio test 
indicated that there was evidence of an interaction between adherence 
and treatment assignment, and the odds of smoking cessation at delivery 
(P = .002). Amongst the women who used placebo patches, there was no 
significant increase in the odds of cessation at delivery in those who were 
highly adherent compared to those who had lower adherence (OR 0.94, 
95% CI 0.47 to 1.88, P = .858). However, amongst the women who used 
NRT patches, there was a significant increase in the odds of cessation at 
Table 2. Baseline Participant Characteristics of the Restricted Study Group (n = 167)
Variable
Adherencea
Low High
Overall (n = 167)Placebo (n = 24) NRT (n = 17) Placebo (n = 35) NRT (n = 91)
Age (y) [median (IQR)] 27.6 (16.7–43.3) 24.6 (18.5–40.0) 26.3 (17.8–39.8) 27.4 (16.8–41.1) 25.7 (21.9–32.0)
Primiparous 50.0% 23.5% 40.0% 35.2% 37.1%
Age full-time education finished
 ≤16 62.5% 76.5% 74.3% 67.0% 68.9%
 >16 37.5% 23.5% 25.7% 33.0% 31.1%
Ethnicity
 British–white 95.8% 100.0% 94.3% 96.7% 96.4%
 Other 4.2% 0.0% 5.7% 3.3% 3.6%
Gestational age (wk) [median (IQR)] 16.7 (14.6–20.7) 14.0 (12.7–15.9) 14.4 (13.1–17.0) 14.9 (13.3–19.0) 15.0 (13.3–18.6)
Baseline cotinine (ng/ml) [median (IQR)] 75.0 (58.9–130.0) 68.3 (45.4–116.3) 80.2 (39.2–124.8) 99.9 (62.0–163.2) 91.2 (57.5–137.7)
Cigarettes currently smoked [mean (SD)] 12.8 (6.6) 13.1 (7.8) 10.0 (5.4) 12.8 (6.4) 12.2 (6.5)
IQR = interquartile range; NRT = nicotine replacement therapy.
aHigh adherence based on median split of adherence at 1-month follow-up.
Table 1. Baseline Participant Characteristics of the Main Study Group (n = 957)
Variable
Adherencea
Low High
Overall (n = 957)Placebo (n = 289) NRT (n = 235) Placebo (n = 194) NRT (n = 239)
Age (y) [median (IQR)] 24.8 (21.2–30.7) 24.8 (21.5–28.7) 25.9 (21.7–30.9) 25.6 (21.4–31.0) 25.1 (21.5–30.7)
Primiparous 36.3% 35.2% 35.7% 39.9% 36.9%
Age full-time education finished
 ≤16 77.6% 79.6% 79.0% 77.9% 78.4%
 >16 22.4% 20.4% 21.0% 22.1% 21.5%
Ethnicity
 British–white 96.5% 96.8% 98.7% 96.9% 97.2%
 Other 3.5% 3.2% 1.3% 3.1% 2.8%
Gestational age (wk) [median (IQR)] 15.6 (13.7–18.7) 15.0 (13.4–18.1) 14.9 (13.4–18.0) 15.0 (13.3–18.3) 15.1 (13.4–18.3)
Baseline cotinine (ng/ml) [median (IQR)] 124.0 (74.5–180.8) 123.8 (87.1–178.4) 114.4 (79.6–167.6) 118.5 (73.5–179.8) 121.2 (78.1–176.1)
Cigarettes currently smoked [mean (SD)] 14.0 (6.1) 15.2 (7.6) 13.5 (6.3) 13.0 (5.9) 13.9 (6.6)
IQR = interquartile range; NRT = nicotine replacement therapy.
aHigh adherence based on median split of adherence at 1-month follow-up.
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delivery in those who were highly adherent compared to those who had 
lower adherence (OR 2.47, 95% CI 1.32 to 4.63, P = .004).
In the sensitivity analysis restricted to a subgroup of women who 
were abstinent at 1 month postquit date (N = 167), the likelihood ratio 
test found no evidence of an interaction between adherence to treatment 
and treatment assignment on the odds of cessation at delivery (P = .151).
Discussion
Main Findings
In this trial, women allocated to active NRT patches had greater 
adherence than women allocated to placebo patches and pregnant 
smokers who were more dependent used patches for fewer days 
than less dependent women. After adjusting for confounding, we 
found a strong positive relationship between adherence to treatment 
and cessation. This association was modified by whether the patch 
contained NRT; there was no evidence that greater use of placebo 
patch was associated with cessation but there was a strong associa-
tion with active patch. We could not exclude reverse causation as an 
explanation for either the overall adherence-cessation relationship 
or its moderation by the content of transdermal patches.
Strengths and Limitations
Strengths of this study include its novelty, size and the rigor of data 
collection, and of analysis techniques employed; it is only the second 
study to investigate adherence to NRT in pregnant quitters, but is 
almost 10 times larger than the earlier study11 and is the first to 
employ multivariable methods to adjust for confounding. As such 
Table 3. Univariable and Multivariable Associations With Adherence Reported at 1 Month
Variable N
Crude 95% CI
P
Adjusted 95% CI LRT
β Lower Upper β Lower Upper P
Age (y) 957 0.07 −0.02 0.16 .144 — — — —
Ethnicity
 Other 27 −1.65 −5.00 1.70 .333 — — — —
 British–white 930 ref — — — — —
Age full-time education finished
 ≤16 751 ref — — .044 — — — —
 >16 206 1.38 0.03 2.73 — — —
Heaviness of smoking index (HSI)
 0–3 631 ref — — .033 — — — —
 4–6 326 −1.27 −2.44 −0.11 — — —
Partners’ smoking status
 Nonsmoking 225 ref — — .627 — — — —
 Smoking 654 0.25 −1.08 1.57 — — —
 Not applicable 78 1.11 −1.15 3.36 — — —
Parity
 ≤1 649 ref — — .933 — — — —
 2 or 3 256 −0.19 −1.46 1.08 — — —
 ≥4 52 −0.34 −2.81 2.14 — — —
Baseline cotinine (ng × 10−1/ml)
 12.1 (7.8–17.6), median (IQR) 957 −0.08 −0.15 −0.01 .021 −0.08 −0.15 −0.01 .020
BMI
 <18.5 28 1.43 −1.93 4.79 .324 — — — —
 18.5–24.9 362 ref — — — — —
 25–29.9 267 1.17 −0.22 2.55 — — —
 >30 254 0.60 −0.80 2.00 — — —
 Missing 46 2.23 −0.45 4.91 — — —
Length of first behavioral support session
 16–30 143 ref — — .585 — — — —
 31–45 791 −0.06 −1.61 1.50 — — —
 >60 23 −1.95 −5.81 1.90 — — —
Previous preterm births
 0 872 ref — — .608 — — — —
 ≥1 85 0.51 −1.44 2.46 — — —
Previous use of NRT
 No 914 ref — — .136 — — — —
 Yes 43 2.03 −0.64 4.71 — — —
Gestational age (wk)
 12–19 766 ref — — .572 — — — —
 20–24 191 −0.40 −1.78 0.99 — — —
Treatment assignment
 Placebo 483 ref — — <.001 ref — — <.001
 NRT 474 2.67 1.58 3.77 2.59 1.50 3.68
BMI = body mass index; CI = confidence interval; IQR = interquartile range; LRT = likelihood ratio test; NRT = nicotine replacement therapy.
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it adds substantially to the evidence base on adherence to NRT in 
pregnancy. Other strengths are that data were obtained as part of 
a well-conducted randomized controlled trial with validated smok-
ing and adherence data available at two time points having been 
obtained by specially-trained research midwives.
One limitation of this analysis is that adherence was self-reported 
so women may have over or under-estimated use of treatment. 
Women who failed to achieve abstinence might have felt pressure 
to over-report use of patches; however, this would be expected to 
weaken the observed association between adherence and cessation 
and thus this is unlikely to create a spurious association between 
the two. Furthermore, retrospective self-reported adherence does not 
allow us to investigate women’s day to day pattern of NRT use, 
which might provide further detail into when might be most effective 
for pregnant women to use NRT for smoking cessation. Future stud-
ies should aim to record this through use of daily diaries or through 
use of electronic form or App. Another limitation is that some moti-
vational factors that have previously been found to predict treatment 
success14 were not collected in the SNAP trial. As it was not pos-
sible to adjust for variables which had not been collected, residual 
confounding by nonmeasured motivational factors could explain the 
relationship between adherence and cessation. For example, stronger 
motivation to quit might result in women smoking less and more 
motivated women might also be expected to adhere better to patch 
treatment, explaining the relationship between adherence and lower 
levels of nicotine addiction. Other factors include the level of social 
Table 4. Univariable and Multivariable Associations With Adherence Reported at Delivery
Variable N
Crude 95% CI
P
Adjusted 95% CI LRT
βa Lower Upper βa Lower Upper P
Age (y) 957 0.01 −0.01 0.03 .154 — — — —
Ethnicity
 Other 27 −0.41 −1.07 0.25 .224 — — — —
 British–white 930 ref — — — — —
Age full-time education finished
 ≤16 751 ref — — .048 — — — —
 >16 206 0.27 0.00 0.53 — — —
Heaviness of smoking index (HSI)
 0–3 631 ref — — .026 ref — — <.001
 4–6 326 −0.26 −0.49 −0.03 −0.27 −0.50 −0.05
Partners’ smoking status
 Nonsmoking 225 ref — — .811 — — — —
 Smoking 654 0.08 −0.18 0.34 — — —
 Not applicable 78 0.11 −0.34 0.55 — — —
Parity
 ≤1 649 ref — — .654 — — — —
 2 or 3 256 −0.08 −0.33 0.17 — — —
 ≥4 52 0.14 −0.34 0.63 — — —
Baseline cotinine (ng × 10−1/ml)
 12.1 (7.8–17.6), median (IQR) 957 −0.01 −0.03 0.00 .053 — — — —
BMI
 <18.5 28 0.10 −0.56 0.77 .228 — — — —
 18.5–24.9 362 ref — — — — —
 25–29.9 267 0.32 0.05 0.60 — — —
 >30 254 0.10 −0.18 0.37 — — —
 Missing 46 0.22 −0.31 0.75 — — —
Length of first behavioral support session
 16–30 143 ref — — .471 — — — —
 31–45 791 0.06 −0.25 0.36 — — —
 >60 23 −0.38 −1.14 0.38 — — —
Previous preterm births
 0 872 ref — — .496 — — — —
 ≥1 85 0.13 −0.25 0.52 — — —
Previous use of NRT
 No 914 ref — — .282 — — — —
 Yes 43 0.29 −0.24 0.82 — — —
Gestational age (wk)
 12–19 766 ref — — .963 — — — —
 20–24 191 0.01 −0.27 0.28 — — —
Treatment assignment
 Placebo 483 ref — — <.001 ref — — <.001
 NRT 474 0.50 0.29 0.72 0.51 0.29 0.72
BMI = body mass index; CI = confidence interval; LRT = likelihood ratio test; NRT = nicotine replacement therapy.
aβ value and regression coefficients using square root transformed adherence.
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support received from other family members in quitting or whether 
women experienced stress during pregnancy, both of which could 
influence adherence to NRT and have been found to be associated 
with cessation; future studies should attempt to collect these vari-
ables to limit residual confounding.14 However, this alone would not 
fully explain the better outcomes seen amongst women with stronger 
adherence to nicotine patches. A further limitation is that only 167 
women were abstinent at 1 month; hence, sensitivity analyses within 
this subgroup, which investigated the adherence-cessation relation-
ship and its moderation, may be underpowered. Consequently, not 
finding a positive association between treatment adherence (ie, pla-
cebo or nicotine) and cessation in this subgroup could either be 
because reverse causality explains this relationship within the larger 
group or because there is insufficient power in the restricted sub-
group to detect such an association. This may be particularly impor-
tant as, using these analysis methods, the strength of any association 
between adherence early in a quit attempt and much later relapse, is 
assessing only adherence around the time of a potential relapse. The 
analysis, therefore, relies on the assumption that early adherence is 
associated with later adherence and the degree to which these two 
are imperfectly correlated will also undermine the apparent strength 
of the association between adherence and relapse.
Findings in the Context of Previous Work
Adherence to medications in pregnancy generally is low15 and very 
little is known about adherence to NRT in pregnancy; findings from 
the only previous study are summarized in the introduction. However, 
adherence to NRT by nonpregnant smokers does seem important 
for achieving smoking cessation. A systematic review investigating 
the relationship between adherence to smoking cessation pharmaco-
therapy and cessation in nonpregnant smokers concluded that “lack 
of adherence to NRT regimens undermines effectiveness in clini-
cal studies.”7 This review only considered studies in which analytic 
strategies employed meant that reverse causation could not explain 
any demonstrated adherence-cessation relationships; only four stud-
ies meeting this criterion were identified and all involved NRT. Two 
studies were underpowered, but the remaining adequately-powered 
ones showed that in the absence of potential reverse causation, 
adherence to NRT resulted in higher cessation rates.
Findings from analyses presented in this paper require careful 
interpretation. There are three possible explanations of the associa-
tion between adherence and cessation. The first is reverse causation; 
women who fail in a quit attempt stop using patches, as instructed, 
and thus failure to achieve abstinence causes low adherence. This 
is supported by our finding that higher dependence, known to be 
associated with early relapse,16 was associated with lower adher-
ence. Studies that do not take reverse causation into account may 
overestimate the strength of association between adherence and ces-
sation; this is the first study that takes account of reverse causa-
tion in an investigation of the association between adherence and 
cessation in pregnancy. Nevertheless, this may not be the complete 
explanation of the association because, even controlling for mark-
ers of dependence, we observed an association between adherence 
and cessation. The second is that a person who follows behavio-
ral advice and adheres to medication is also more prone to follow 
other behavioral advice and show greater self-control and therefore 
more likely to achieve cessation, independently of any benefit of 
medication. This explanation is not supported by our data, however. 
Table 5. Multivariable Associations With Validated Cessation at 1 Month (n = 957, 91.1%)
Variable N Adjusted OR
95% CI LRT
Lower Upper P
Adherence 0–28 days 957 1.11 1.09 1.13 <.001
Age full-time education finished
 ≤16 751 ref — — .044
 >16 206 1.54 1.01 2.35
Heaviness of smoking index (HSI)
 0–3 631 ref — — .001
 4–6 326 0.75 0.63 0.88
Baseline cotinine (ng × 10−1/ml) 957 0.94 0.91 0.97 <.001
Treatment assignment
 Placebo 483 ref — — .004
 NRT 474 1.77 1.20 2.61
CI = confidence interval; LRT = likelihood ratio test; NRT = nicotine replacement therapy; OR = odds ratio.
Table 6. Multivariable Associations With Validated Cessation at Delivery (n = 957, 91.1%)
Variable N
Adjusted 95% Confidence Interval LRT
OR Lower Upper P
Adherence 0–56 days 957 1.06 1.03 1.09 <.001
Heaviness of smoking index (HSI)
 0–3 631 ref — — .002
 4–6 326 0.74 0.61 0.89
Treatment assignment
 Placebo 483 ref — — .355
 NRT 474 1.25 0.78 2.00
LRT = likelihood ratio test; NRT = nicotine replacement therapy; OR = odds ratio.
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Women allocated to placebo who adhered to their treatment regi-
men were not more likely to achieve cessation than women who did 
not adhere well, whereas women allocated to nicotine patches were. 
This supports the third explanation, which is that higher adherence 
to nicotine-containing patches prevents relapse. Unfortunately, our 
analyses in the “restricted” sample in which reverse causation was 
not possible did not provide further evidence for this explanation. 
Taken together, though, the data do indicate that poor adherence 
to NRT may be a particular problem in pregnancy and suggest that 
future trials of NRT in pregnancy may need to pay particular atten-
tion to the behavioral components to support greater adherence to 
medication.
Conclusions
Adherence to treatment was associated with smoking cessation but 
it is not clear if this was due to active NRT treatment being effec-
tive, reverse causation or if the propensity to adhere to treatment 
was indicative of (unmeasured) women’s characteristics which made 
them more likely to achieve abstinence anyway. As a key influence 
on adherence was the provision of nicotine and at similar adherence 
levels, NRT patches were associated with greater odds of cessation 
than placebo ones, a likely hypothesis is that NRT patches, if used 
sufficiently, may be effective for smoking cessation in pregnancy.
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